Cloud Computing in the Pharmaceutical Industry
Pharmaceutical Technology
OCTOBER 2, 2024
Discover the leading providers of cloud computing in the pharmaceutical industry. Download the free Buyer's Guide for full contact details.
Wed.Oct 02, 2024
130 
How Roche plans to fill a projected $8B sales gap
Bio Pharma Dive
OCTOBER 2, 2024
Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Exscientia outline robot and AI use in drug discovery workflow
Pharmaceutical Technology
OCTOBER 2, 2024
Exscientia detailed how its robotics lab in Oxfordshire, UK is increasing productivity and efficiency in developing new molecules at ELRIG 2024.
Your Smartphone Could Soon Measure Your Blood Pressure With Just a Touch
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 2, 2024
(akaratwimages/Canva) High blood pressure (or hypertension) increases the risk of health problems such as heart or kidney failure, but goes undiagnosed in millions of people.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
LoQus23 secures $43m to advance Huntington’s Disease therapy
Pharmaceutical Technology
OCTOBER 2, 2024
The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.
With $115M more, Triveni accelerates immune drug work
Bio Pharma Dive
OCTOBER 2, 2024
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Gilead agrees to license new HIV drug in low-income countries
Bio Pharma Dive
OCTOBER 2, 2024
The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease but limited resources.
October 2, 2024: In This Week’s PCT Grand Rounds, a Novel Health System–Public Health Partnership
Rethinking Clinical Trials
OCTOBER 2, 2024
In this Friday’s PCT Grand Rounds, Tyler Winkelman of Hennepin Healthcare and the Hennepin Healthcare Research Institute, and David Johnson of Hennepin County, will present “Health Trends Across Communities – A Novel Health System-Public Health Data Partnership.” The Grand Rounds session will be held on Friday, October 4, 2024, at 1:00 pm eastern.
Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy
Pharma Times
OCTOBER 2, 2024
ISM001-055 shows promise in improving lung function among patients
Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med
Fierce Pharma
OCTOBER 2, 2024
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug, lenacapivir, in 120 resource-limited countries.
Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
Bio Pharma Dive
OCTOBER 2, 2024
It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the drug and biologic copycats.
Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility
Fierce Pharma
OCTOBER 2, 2024
Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31
Triveni scores $115m to expand immunology pipeline
Pharmaceutical Technology
OCTOBER 2, 2024
The Series B funds will expedite pipeline expansion and cover a clinical proof-of-concept study for TRIV-573.
J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study
Fierce Pharma
OCTOBER 2, 2024
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi has held a larger slice of the market than Johnson & Johnson’s riva | A real-world, head-to-head study of two androgen receptor pathway inhibiting (ARPI) prostate cancer drugs indicates that Johnson & Johnson’s Erleada provides an edge in overall survival versus Astellas and Pfizer’s Xtandi.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec
Pharmaceutical Technology
OCTOBER 2, 2024
Focus is turning to the development of peptide analogs of antibody-derived radiotherapeutics, according to Dr. Dave Madge.
Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing
Bio Pharma Dive
OCTOBER 2, 2024
With its latest investment, Lilly is looking toward medicines of the future and new methods to produce them.
Shattuck Labs stock craters following pipeline and job cuts
Pharmaceutical Technology
OCTOBER 2, 2024
The cash-saving measures come after interim analysis showed the company’s lead cancer drug only showed modest improvement in survival.
Amgen can't sidestep investor lawsuit over $10.7B tax bill
Fierce Pharma
OCTOBER 2, 2024
Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IR | New York District Judge John Cronan has rejected Amgen’s motion to dismiss an investor lawsuit—originally filed by a Michigan-based union pension fund—accusing the company of hiding a $10.7-billion tax bill from the public.
AlzeCure’s ACD856’s effects to be presented at Alzheimer’s conference
Pharma Times
OCTOBER 2, 2024
Preclinical data on NeuroRestore therapy to be showcased at CTAD in Madrid
Amgen to face investor lawsuit over $10.7bn tax liability disclosure
pharmaphorum
OCTOBER 2, 2024
A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.
Pharma Plant Sleuthing: 8 Ways to Find Manufacturing Capacity as an Outsider
Drug Patent Watch
OCTOBER 2, 2024
As an outsider, finding out the manufacturing capacity of a given pharmaceutical manufacturing plant can be challenging due to the proprietary nature of such information. However, you can employ several strategies to gather relevant data: Example: Pfizer’s 2022 Annual Report states, “Our manufacturing facilities are located in 39 countries across 6 continents.
The patient will see you now: Why embracing discomfort could transform patient engagement
pharmaphorum
OCTOBER 2, 2024
The patient will see you now: Why embracing discomfort could transform patient engagement Mike.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Navigating Privacy and Personalization in Pharma Advertising with Emily Keith
Fierce Pharma
OCTOBER 2, 2024
Sitting down with Emily Keith, SVP at AdTheorent Health, at Digital Pharma East 2024, we explored the cutting-edge int | Sitting down with Emily Keith, SVP at AdTheorent Health, at Digital Pharma East 2024, we explored the cutting-edge intersection of healthcare, advertising and privacy.
Closed and Collaborative: Mergers, acquisitions, and partnerships in August 2024
pharmaphorum
OCTOBER 2, 2024
Explore the mergers, acquisitions, and partnerships in August 2024. Discover how these collaborations are shaping the business landscape.
New CTTI Project Aims to Offer Clarity Around Implementing Flexible Clinical Trial Approaches While Maintaining Data Quality
CTTI (Clinical Trials Transformation Initiative)
OCTOBER 2, 2024
Implementing less rigid, more flexible approaches to clinical trials can increase patient and site access to research, improve participant satisfaction, facilitate real-world data use, enroll more diverse patient populations, and enable more generalizable trial results. Ultimately, these flexible trial approaches help sponsors bring new therapies to patients faster.
FDA issues summary of grants, promotes rare disease research
pharmaphorum
OCTOBER 2, 2024
FDA issues summary of grants, promotes rare disease research Nicole.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Indeterminate Change: FDA Releases Draft Guidance on Predetermined Change Control Plans for Medical Devices
FDA Law Blog
OCTOBER 2, 2024
By Adrienne R. Lenz, Principal Medical Device Regulation Expert & Lisa M. Baumhardt, Senior Medical Device Regulation Expert & Gail H. Javitt — A recent draft guidance on predetermined change control plans (PCCP) for medical devices continues FDA’s effort to implement Section 515C of the Food and Drug Omnibus Reform Act of 2022 (FDORA), which Congress enacted to make it easier for manufacturers to make post-market device changes by avoiding the need for additional FDA authorization (se
Revisionist history on healthcare at the VP debate
pharmaphorum
OCTOBER 2, 2024
In the VP debate, Tim Walz and JD Vance were forceful, unexpectedly convivial, and fast and loose with the facts, particularly on healthcare.
CPHI 2024: Stevanato to unveil large-volume injectable platform
BioPharma Reporter
OCTOBER 2, 2024
The company, a provider of drug containment and delivery solutions, will introduce its expanded Vertiva 10mL on-body delivery system.
Blue Shield of California bypasses PBMs to slash Humira prices by 90%
pharmaphorum
OCTOBER 2, 2024
In a bold move to tackle soaring drug costs, Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the cost of Humira by 90%
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content